BCL2 and prostate carcinoma: To the best of our knowledge, the predicted target mRNAs of miR-193b, miR-195 and miR-7 have yet to be functionally validated; whereas BCL2, BCL2L11 (Bim) and CDN1B (p 27) have been functionally validated (by Western blot or qRT-PCR analysis) as target mRNAs of miR-34a, miR-221 and miR-222 in human neuroblastoma, prostate cancer and rat PC12 cell lines [40-42].